Literature DB >> 23541530

The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.

Darkhan Utepbergenov1, Zygmunt S Derewenda.   

Abstract

All known protein kinases share a bilobal kinase domain with well conserved structural elements. Because of significant structural similarities of nucleotide binding pocket, the development of highly selective kinase inhibitors is a very challenging task. Flavonols, naturally occurring plant metabolites, have long been known to inhibit kinases by mimicking the adenine moiety. Interestingly, recent data show that some flavonol glycosides are more selective, although underlying mechanisms were unknown. Crystallographic data from our laboratory revealed that the N-terminal kinase domain of p90 ribosomal S6 kinase, isoform 2, binds three different flavonol rhamnosides in a highly unusual manner, distinct from other kinase inhibitor interactions. The kinase domain undergoes a reorganization of several structural elements in response to the binding of the inhibitors. Specifically, the main β-sheet of the N-lobe undergoes a twisting rotation by ~56° around an axis passing through the N- and C-lobes, leading to the restructuring of the canonical ATP-binding pocket into pockets sterically adapted to the inhibitor shape. The flavonol rhamnosides appear to adopt compact, but strained conformations with the rhamnose moiety swept under the B-ring of flavonol, unlike the structure of the free counterparts in solution. These data suggest that the flavonol glycoside scaffold could be used as a template for new inhibitors selective for the RSK family. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases (2012). Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541530      PMCID: PMC3683371          DOI: 10.1016/j.bbapap.2013.03.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  47 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Sequence and structural analysis of kinase ATP pocket residues.

Authors:  Anna Vulpetti; Roberta Bosotti
Journal:  Farmaco       Date:  2004-10

3.  Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.

Authors:  Jeffrey A Smith; David J Maloney; David E Clark; Yaming Xu; Sidney M Hecht; Deborah A Lannigan
Journal:  Bioorg Med Chem       Date:  2006-05-24       Impact factor: 3.641

4.  Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

Authors:  Darkhan Utepbergenov; Urszula Derewenda; Natalya Olekhnovich; Gabriela Szukalska; Budhaditya Banerjee; Michael K Hilinski; Deborah A Lannigan; P Todd Stukenberg; Zygmunt S Derewenda
Journal:  Biochemistry       Date:  2012-08-06       Impact factor: 3.162

5.  Dietary flavonoids: intake, health effects and bioavailability.

Authors:  P C Hollman; M B Katan
Journal:  Food Chem Toxicol       Date:  1999 Sep-Oct       Impact factor: 6.023

Review 6.  Active and inactive protein kinases: structural basis for regulation.

Authors:  L N Johnson; M E Noble; D J Owen
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

7.  RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells.

Authors:  Ulrik Doehn; Camilla Hauge; Scott R Frank; Claus J Jensen; Katarzyna Duda; Jakob V Nielsen; Michael S Cohen; Jens V Johansen; Benny R Winther; Leif R Lund; Ole Winther; Jack Taunton; Steen H Hansen; Morten Frödin
Journal:  Mol Cell       Date:  2009-08-28       Impact factor: 17.970

Review 8.  Ca(2+)/calmodulin-dependent protein kinases.

Authors:  M T Swulius; M N Waxham
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

Review 9.  RSK in tumorigenesis: connections to steroid signaling.

Authors:  T S Karin Eisinger-Mathason; Josefa Andrade; Deborah A Lannigan
Journal:  Steroids       Date:  2010-01-04       Impact factor: 2.668

10.  Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2.

Authors:  Margarita Malakhova; Igor Kurinov; Kangdong Liu; Duo Zheng; Igor D'Angelo; Jung-Hyun Shim; Valerie Steinman; Ann M Bode; Zigang Dong
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more
  4 in total

1.  Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis.

Authors:  Oriol Morales-Ibanez; Silvia Affò; Daniel Rodrigo-Torres; Delia Blaya; Cristina Millán; Mar Coll; Luis Perea; Gemma Odena; Thomas Knorpp; Markus F Templin; Montserrat Moreno; José Altamirano; Rosa Miquel; Vicente Arroyo; Pere Ginès; Juan Caballería; Pau Sancho-Bru; Ramon Bataller
Journal:  Gut       Date:  2015-02-04       Impact factor: 23.059

2.  Activation of p90 ribosomal S6 kinases by ORF45 of Kaposi's sarcoma-associated herpesvirus is critical for optimal production of infectious viruses.

Authors:  Bishi Fu; Ersheng Kuang; Wenwei Li; Denis Avey; Xiaojuan Li; Zachary Turpin; Ahmed Valdes; Kevin Brulois; Jinjong Myoung; Fanxiu Zhu
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

3.  Identification of afzelin potential targets in inhibiting triple-negative breast cancer cell migration using reverse docking.

Authors:  Eva Rachmi; Basuki Bambang Purnomo; Agustina Tri Endharti; Loeki Enggar Fitri
Journal:  Porto Biomed J       Date:  2020-11-24

4.  RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study.

Authors:  Alejandro M S Mayer; Mary L Hall; Joseph Lach; Jonathan Clifford; Kevin Chandrasena; Caitlin Canton; Maria Kontoyianni; Yeun-Mun Choo; Dev Karan; Mark T Hamann
Journal:  Mar Drugs       Date:  2021-09-07       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.